

## Supplementary Appendix

**Table.** Specifically used regimens in Asia

Location	Induction therapy in young, fit patients	Induction therapy in older, unfit patients	Maintenance therapy	Relapsed/refractory MCL 2nd-line	Relapsed/refractory MCL later line
China	Alternating R-CHOP and R-DHAP followed by auto-HSCT	R-CHOP or lenalidomide	CAR-T used in clinical trial setting	Ibrutinib	Lenalidomide
Hong Kong	R-hyperCVAD or R-BAC; auto-HSCT	R-BAC if patient cannot tolerate ara-C; BR in very old, unfit patients; IR if patient can afford	Rituximab used in some patients	Ibrutinib	Bendamustine, ara-C or venetoclax
Taiwan	Hyper-CVAD or high-dose ara-C or CHOP (rituximab not reimbursed) followed by auto-HSCT	CHOP or CVP, VR-CAP may be an option	N/A	Ara-C	Ara-C
Japan	R-CHOP followed by CHASER then auto-HSCT	BR (mostly) or VR-CAP (less common)	Rituximab recommended per guidelines	Ibrutinib	Bendamustine, CHOP, or R-CHOP
Korea	R-CHOP followed by high-dose ara-C then HSCT; BR preferred but not reimbursed	VR-CAP or R-CHOP followed by high-dose ara-C; BR preferred but not reimbursed	Rituximab used in some patients	Ibrutinib	Bortezomib, lenalidomide or ara-C

Ara-C, cytarabine; Auto-HSCT, autologous hematopoietic stem cell transplantation; BR, bendamustine, rituximab; CAR-T, chimeric antigen receptor T-cell; CHOP, cyclophosphamide, doxorubicin, vincristine, prednisone; CVP, cyclophosphamide, vincristine, prednisone; MCL, mantle cell lymphoma; R-BAC, rituximab, cytarabine, bendamustine; R-CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone; R-DHAP, rituximab, dexamethasone, cytarabine, cisplatin;

R-HyperCVAD, rituximab, hyperfractionated cyclophosphamide, vincristine, doxorubicin, dexametasone, alternating with high-dose methotrexate and cytarabine; VR-CAP, bortezomib, rituximab, cyclophosphamide, doxorubicin, prednisone.